Reshape Lifesciences (NASDAQ:RSLS) Upgraded to “Sell” at ValuEngine

Reshape Lifesciences (NASDAQ:RSLS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday, February 2nd.

Separately, Zacks Investment Research upgraded Reshape Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 17th.

Reshape Lifesciences (RSLS) opened at $1.42 on Friday. Reshape Lifesciences has a twelve month low of $1.23 and a twelve month high of $8.13. The firm has a market capitalization of $42.54, a price-to-earnings ratio of -0.24 and a beta of 2.89.

A hedge fund recently bought a new stake in Reshape Lifesciences stock. Anson Funds Management LP acquired a new stake in shares of Reshape Lifesciences Inc (NASDAQ:RSLS) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 219,016 shares of the medical device company’s stock, valued at approximately $324,000. Anson Funds Management LP owned approximately 0.73% of Reshape Lifesciences as of its most recent SEC filing. Hedge funds and other institutional investors own 0.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Reshape Lifesciences (NASDAQ:RSLS) Upgraded to “Sell” at ValuEngine” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/reshape-lifesciences-rsls-upgraded-to-sell-at-valuengine.html.

About Reshape Lifesciences

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply